Incidence Trends of Vulvar Cancer in the United States: A 20‐Year Population‐Based Study
Cancer Reports · 2024
DOI: 10.1002/cnr2.2120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Seyed Ehsan Mousavi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Vulvar Neoplasms, SEER Program. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite being uncommon, vulvar cancer is a serious health concern with a 5‐year relative survival rate of 71%.
Aims
The objective was to investigate the incidence rates of this disease across different racial, ethnic, and histological subgroups in the United States, as well as the effects of the COVID‐19 pandemic on this cancer.
Methods
We used the Surveillance, Epidemiology, and End Results (SEER) 22 database. The International Classification of Diseases for Oncology Version 3 topologic code C51 was assigned for vulvar cancer. Average annual percent change (AAPC) and the pairwise comparison with the parallelism and coincidence were reported. Counts and age‐adjusted incidence rates per 100 000 individuals with their corresponding 95% confidence intervals (CIs) were reported.
Results
The age‐adjusted incidence rate of vulvar cancer was 2.40 (95% CI, 2.38–2.43) over the period 2000–2019, with an AAPC of 0.80 (95% CI, 0.63–0.99). By race/ethnicity, only non‐Hispanic Whites had an increasing trend over 2000–2019 (AAPC: 1.30; 95% CI, 1.07–1.54). The highest age‐adjusted incidence rate of vulvar cancer in the United States was for squamous cell carcinoma (SCC). There was a significant decrease in the age‐standardized incidence rate of vulvar cancer in all races/ethnicities in all age groups (AAPC: −10.15; 95% CI, −15.35 to −4.94) over 2019–2020. Also, the incidence rates and incident numbers of vulvar cancer increased with aging and peaked at the 85+ age group.
Conclusion
There was an increase in the incidence rate of vulvar cancer in all races, with a significantly increased trend in non‐Hispanic White women from 2000 to 2019. SCC displayed the highest incidence rate among vulvar cancer histological types. It is recommended to conduct further research to identify the relevant risk factors of vulvar cancer in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Community Medicine, Faculty of Medicine, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Center for Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran.
- Calaveras County Department of Health, Calaveras County, California, USA.
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
ORCID-Profile: Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi
Zitieren
APA
Mousavi, S. E., Ghasemi, H., Najafi, M., Yekta, Z., & Nejadghaderi, S. A. (2024). Incidence Trends of Vulvar Cancer in the United States: A 20‐Year Population‐Based Study. Cancer Reports. https://doi.org/10.1002/cnr2.2120
Vancouver
Mousavi SE, Ghasemi H, Najafi M, Yekta Z, Nejadghaderi SA. Incidence Trends of Vulvar Cancer in the United States: A 20‐Year Population‐Based Study. Cancer Reports. 2024. doi:10.1002/cnr2.2120
BibTeX
@article{Mousavi2024,
author = {Mousavi, Seyed Ehsan and Ghasemi, Hoomaan and Najafi, Morvarid and Yekta, Zahra and Nejadghaderi, Seyed Aria},
title = {Incidence Trends of Vulvar Cancer in the United States: A 20‐Year Population‐Based Study},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2120}
}
EUVIMED